[144] SOPHiA GENETICS SA SEC Filing

Rhea-AI Filing Summary

SOPHiA GENETICS SA (SOPH) filed a Form 144 indicating that Ross J. Muken intends to sell up to 14,509 common shares through Morgan Stanley Smith Barney on or about 20 June 2025. At the most recent market price reflected in the filing, the shares have an aggregate value of $44,107.36. The company has 66,687,085 shares outstanding, meaning the proposed sale represents roughly 0.02 % of shares outstanding.

The filing also discloses that, under a Rule 10b5-1 trading plan, Muken has sold 14,542 shares in the prior three months for total gross proceeds of approximately $40,660. The current notice confirms the seller’s representation that no undisclosed material adverse information is known at the time of the planned sale.

Because the transaction size is modest relative to the company’s share count and is executed under a pre-arranged trading plan, the filing is routine and unlikely to have a material impact on SOPH’s capital structure or stock liquidity.

Positive

• Sale size is immaterial at roughly 0.02 % of outstanding shares, limiting dilution or supply concerns.
• Transaction executed under Rule 10b5-1, indicating a pre-planned, transparent process that minimizes insider-timing risk.

Negative

• Continued insider selling (≈29 k shares over three months) may be viewed cautiously by some investors despite small volume.

Insights

Insider Trading Analyst

TL;DR: Small 14.5k-share insider sale under 10b5-1 plan; negligible 0.02 % of float, limited market impact.

The Form 144 shows Ross J. Muken plans to dispose of 14,509 SOPH shares worth roughly $44k. Combined with 14,542 shares already sold since March, total dispositions reach about 29 k shares—still only 0.04 % of the 66.7 m shares outstanding. The use of a 10b5-1 plan suggests the transactions are automated and reduces concerns about opportunistic selling. Given the de-minimis size and absence of any new operational data, I view the disclosure as routine and not valuation-moving.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	14509	44107.36	66687085	06/20/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	06/18/2025	Restricted Stock Units	Issuer			14509	06/18/2025	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
10b5-1 Sales for ROSS J MUKEN La Piece 12 ch-1180 Rolle V8 00000	Common	05/23/2025	131	377.25
10b5-1 Sales for ROSS J MUKEN La Piece 12 ch-1180 Rolle V8 00000	Common	05/19/2025	761	2186.66
10b5-1 Sales for ROSS J MUKEN La Piece 12 ch-1180 Rolle V8 00000	Common	04/23/2025	131	397.69
10b5-1 Sales for ROSS J MUKEN La Piece 12 ch-1180 Rolle V8 00000	Common	04/21/2025	761	2072.13
10b5-1 Sales for ROSS J MUKEN La Piece 12 ch-1180 Rolle V8 00000	Common	04/09/2025	6785	19097.06
10b5-1 Sales for ROSS J MUKEN La Piece 12 ch-1180 Rolle V8 00000	Common	04/08/2025	1877	5185.02
10b5-1 Sales for ROSS J MUKEN La Piece 12 ch-1180 Rolle V8 00000	Common	04/07/2025	1865	4999.88
10b5-1 Sales for ROSS J MUKEN La Piece 12 ch-1180 Rolle V8 00000	Common	04/04/2025	1533	4211.00
10b5-1 Sales for ROSS J MUKEN La Piece 12 ch-1180 Rolle V8 00000	Common	04/03/2025	567	1726.97
10b5-1 Sales for ROSS J MUKEN La Piece 12 ch-1180 Rolle V8 00000	Common	03/24/2025	131	407.41

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

How many SOPH shares does Ross J. Muken plan to sell according to the Form 144?

The notice covers 14,509 common shares to be sold.

What is the value of the proposed SOPH share sale?

The aggregate market value stated is $44,107.36.

What percentage of SOPHiA GENETICS' shares outstanding does the planned sale represent?

Approximately 0.02 % of the 66,687,085 shares outstanding.

Were there prior insider sales disclosed in the filing?

Yes. The filing lists 14,542 shares sold across ten transactions in the last three months.

Is the sale being executed under a Rule 10b5-1 trading plan?

Yes. The filing cites 10b5-1 sales, indicating a pre-arranged plan.